limited direct GLP-1 pipeline exposure #7 Pfizer Inc
Im not gonna judge anybody, Roker told the Daily Mail
pharmaphorum news pharmaphorum news 3,495 followers More articles by pharmaphorum Jul 27, 2026 Trump sets course for 100%, then 200%, tariffs on generics - TOP STORIES - 27.07.26 In this weeks Top Stories, Donald Trump announced plans to impose tariffs of 100% on generic drugs imported into the Jul 24, 2026 Re-rostered FDA committee backs peptide compounding - NEWS - 24.07.26 This Friday, the recently revamped FDA Pharmacy Compounding Advisory Committee has narrowly voted in favour of Jul 23, 2026 EU clears AZ's SERD camizestrant, as FDA review drags on - NEWS - 23.07.26 This Thursday, AstraZeneca's new breast cancer therapy Etcamah has claimed landmark frontline approval for use in the Jul 22, 2026 Trump announces 100% tariff on generics imports - NEWS - 22.07.26 The Trump Administration's pharmaceutical tariffs are back with a new target: generic medicines, which will see a 100% Jul 21, 2026 New UK PM shuts down science and tech department - NEWS - 21.07.26 This Tuesday, the UK's new Prime Minister Andy Burnham has abolished the Department for Science, Innovation and Jul 20, 2026 Novo's Wegovy pill cleared for weight loss in EU - TOP STORIES - 20.07.26 In this weeks Top Stories, the EU approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the Jul 17, 2026 MSD gets first FDA okay for oral PCSK9 cholesterol drug - NEWS - 17.07.26 This Friday, MSD has claimed a first in cardiovascular medicine after winning FDA approval for Lipfendra, the first Jul 16, 2026 Novo's Wegovy pill cleared for weight loss in EU - NEWS - 16.07.26 This Thursday, Novo Nordisk has secured European approval for its Wegovy pill, making it the first oral GLP-1 agonist Jul 15, 2026 Celcuity gets FDA nod for first-in-class breast cancer drug - NEWS - 15.07.26 This Wednesday, Celcuity has won FDA approval for gedatolisib its first product as a treatment for patients with a Jul 14, 2026 AstraZeneca adds another Chinese asset, from Dizal - NEWS - 14.07.26 This Tuesday, AstraZeneca has continued its dealmaking spree in China, signing a $1.5 billion agreement with Dizal Explore content categories
Duration of Effectiveness : Semaglutide : Long-term treatment, with weight loss benefits observed over extended periods
Dosing errors at higher concentrations can cause severe side effects or waste expensive medication
Full story here: To view or add a comment, sign in HRSA's launch today of its 340B rebate pilot program is good for participating drug manufacturers but not for safety-net providers or the patients they serve
